Compositions and Methods which modulate G-Protein Signaling for the Treatment of Inflammatory Disorders such as Asthma and Allergic Conjunctivitis

Abstract

Compositions and methods for the treatment of asthma and inflammatory ocular disorders are disclosed.

1 - 10 . (canceled) 
     
     
         11 . A method for the treatment of inflammatory disorders of the eye associated with aberrant beta adrenergic signaling in a patient in need thereof, comprising administration of an effective amount of an inhibitor of Gβγ signaling, said administration being effective to reduce ocular inflammation in said patient. 
     
     
         12 . The method of  claim 11 , wherein said disorder is selected from the group consisting of allergic conjunctivitis, non-allergic conjunctivitis and inflammation associated with exposure to chemical irritants. 
     
     
         13 . The method of  claim 11 , wherein said inhibitor of Gβγ signaling selected from the group consisting of a membrane permeable Gβγ blocking peptide, cyclohexanecarboxylic acid [2-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9-yl)-(9Cl)], gallein, M119, βARKct, phosducin fragment containing amino acids 217-246, and phosducin fragment containing amino acids 213-233, wherein said inhibitor is optionally linked to a membrane permeable carrier. 
     
     
         14 . The method of  claim 13  wherein said inhibitor of Gβγ signaling is a membrane permeable Gβγ blocking peptide comprising SEQ ID NO: 1. 
     
     
         15 . The method of  claim 14 , wherein said peptide is delivered topically in a biologically acceptable carrier. 
     
     
         16 . The method of  claim 14 , wherein said peptide is delivered in an ocular implant. 
     
     
         17 . A method for treating an inflammatory disorder associated with aberrant beta adrenergic signaling in a patient in need thereof, comprising administration of an effective amount of an anti-Gβγ peptide comprising SEQ ID NO: 1 in a biologically acceptable carrier, said peptide being effective to reduce inflammation in said subject. 
     
     
         18 . The method of  claim 17 , wherein said inflammatory disorder is selected from the group consisting of allergic rhinitis, atopic dermatitis, non allergic rhinitis and dermatitis induced by chemical irritants. 
     
     
         19 . The method of  claim 17 , wherein said peptide is administered via a route selected from the group consisting of topical, intra-ocular, intra-peritoneal, intra-nasal, intra-muscular, and systemic.